Biomarkers predictive of embryo quality and clinical pregnancy in women prior to undergoing antagonist treatment assisted reproductive therapy

Drop Bio Pty Ltd0 个研究点目标入组 400 人开始时间: 2021年10月18日最近更新: 2022年10月3日

适应症

试验速览

暂无简介。

•1. Seeking and undergoing fertility treatment at one of Virtus Health’s three major Sydney clinics (Alexandria, Greenwich and Westmead)
•3. 18 - 42 years of age
•4. Antagonist treatment protocol
•5. Autologous oocyte
•6. In vitro fertilisation (IVF)
•7. Intracytoplasmic sperm injection (ICSI)
•8. Scheduled for a blood collection within the first 72h of menses

•1. Male-factor infertility defined by Australia and New Zealand Assisted Reproduction Database (ANZARD) in patient history
•2. Undertaking assisted reproductive therapy (ART) and oocyte or embryo freeze all for fertility preservation
•3. Body Mass Index greater than 35kg.m2 or less than 18.5kg.m2
•4. Currently receiving steroid based therapy in the last two weeks
•5. Recent antimicrobial treatment n the last two weeks
•6. Recent iron infusion OR infusion/transfusion based therapy n the last 12 weeks
•7. Genetic disorder(s) diagnosis
•8. Any past history of chemotherapy
•9. Autoimmune disorder(s) diagnosis
•10. Recent surgery within n the last 12 weeks
•11. Acute illness, such as an infection, within the last two weeks
•12. Renal impairment diagnosis
•13. Liver dysfunction diagnosis and or significant hypoalbuminaemic state

发起方

Drop Bio Pty Ltd